Market revenue in 2023 | USD 223.6 million |
Market revenue in 2030 | USD 426.9 million |
Growth rate | 9.7% (CAGR from 2023 to 2030) |
Largest segment | Hereditary non-cancer testing |
Fastest growing segment | Hereditary Non-cancer Testing |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Hereditary Cancer Testing, Hereditary Non-cancer Testing |
Key market players worldwide | Myriad Genetics Inc, Invitae Corp, Illumina Inc, Natera Inc, Labcorp Holdings Inc, Roche Holding AG ADR, Quest Diagnostics Inc, CooperSurgical, Agilent Technologies Inc, Thermo Fisher Scientific Inc, Twist Bioscience Corp, Sophia Genetics SA, Fulgent Genetics Inc, MedGenome, Centogene NV Ordinary Shares, The Cooper Companies Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to hereditary testing market will help companies and investors design strategic landscapes.
Hereditary non-cancer testing was the largest segment with a revenue share of 78.62% in 2023. Horizon Databook has segmented the UK hereditary testing market based on hereditary cancer testing, hereditary non-cancer testing covering the revenue growth of each sub-segment from 2018 to 2030.
The UK Genetic Testing Network (UKGTN) is an advisory organization for National Health Service’s (NHS) clinical genetic testing services. This network promotes access to genetic testing and offers support to the NHS.
It provides a database of genetic test services provided by several laboratories and companies for diagnosing rare genetic conditions. There is an increasing demand for Noninvasive Prenatal Testing (NIPT) for decision-making related to pregnancy management, for reassurance in early pregnancy, and information only.
In January 2016, the UK National Screening Committee proposed an evaluative approach to offer NIPT for aneuploidies in pregnant women whose babies have a risk greater than 1 in 150 of developing these conditions, following combined test at 10 to 14 weeks.
Horizon Databook provides a detailed overview of country-level data and insights on the UK hereditary testing market, including forecasts for subscribers. This country databook contains high-level insights into UK hereditary testing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account